enGene Therapeuti…
CACADenGene Therapeutics Inc. (US:ENGN) — Biotechnology: Biological Products (No Diagnostic Substances). Börside arv, kus ettevõtte aktsiatega kaubeldakse: 1. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte Kohta
- Veebileht
- engene.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Peakontor
- SAINT-LAURENT, Canada
- Tegevjuht
- Ronald H. W. Cooper
- Töötajad
- 81
- Ringluses Olevad Aktsiad
- 67.02 mln seisuga 2026-09-02
- Vabalt Kaubeldavad Aktsiad
- 32.75 mln
- Turukapitalisatsioon
- 132.02 mln USD
- Siseringi Isikud
- 0.11%
- Institutsionaalsed Investorid
- 84.11%
- Tegevusala (SIC)
- Biological Products, (No Diagnostic Substances)
- P/E
- kahjum
- FCF
- −104 mln USD
- Võlg
- 25.2 mln USDnetoraha
- Kasum ja FCF — 12 kuu jooksul kuni 31.07.2026 (ettevõtte viimane raport).
- NAV
Kirjeldus
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Börsid ja Tikkerid
| Börs | Tikker | Valuuta | Hind | Tüüp |
|---|---|---|---|---|
| US USA Stocks | ENGN | USD | 1.71 +9.62% | tavalised aktsiad |
Suurimad Omanikud
| Omanik | Osalus | Aktsiad | Aruande Kuupäev |
|---|---|---|---|
| FCPM III Services B.V. | 14.37% | 9.63 mln | 2026-06-30 |
| BML Capital Management,… | 9.95% | 6.67 mln | 2026-06-30 |
| Siren, L.L.C. | 9.34% | 6.26 mln | 2026-06-30 |
| Perceptive Advisors Llc | 7.2% | 4.82 mln | 2026-06-30 |
| Ameriprise Financial, In… | 3.99% | 2.68 mln | 2026-06-30 |
| Nextech Invest, Ltd. | 3.47% | 2.32 mln | 2026-06-30 |
| Adar1 Capital Management… | 3.14% | 2.1 mln | 2026-06-30 |
| Vestal Point Capital, LP | 2.49% | 1.67 mln | 2026-06-30 |
| Acorn Capital Advisors,… | 1.9% | 1.27 mln | 2026-06-30 |
| Peapod Lane Capital LLC | 1.64% | 1.1 mln | 2026-06-30 |
| Franklin Strategic Serie… | 0.73% | 486 579 | 2026-04-30 |
| Fidelity Concord Street… | 0.05% | 34 982 | 2026-07-31 |
| ETFis Series Trust I-Vir… | 0.05% | 32 625 | 2026-04-30 |
| TIFF INVESTMENT PROGRAM-… | 0.02% | 10 639 | 2026-06-30 |
| JNL Series Trust-JNL/DFA… | 0.01% | 9 974 | 2026-06-30 |
| Exchange Place Advisors… | 0.01% | 7 649 | 2026-06-30 |
| GROSSMAN WILLIAM (Office… | ≈0.01% | 5 102 | 2026-09-22 |
| Advanced Series Trust-AS… | 0% | 1 376 | 2026-06-30 |
| FORBION GROWTH OPPORTUNI… | — | — | 2024-10-30 |
Logi Sisse Google